Cardiogen 20mg

Researchers evaluating Cardiogen should start with identity, COA, analytical testing, and RUO labeling. Cardiogen is commonly mapped to H-Ala-Glu-Asp-Arg-OH, a four-residue peptide sequence listed by PubChem as AEDR with molecular formula C18H31N7O9 and molecular weight 489.5 g/mol [1] . Literature provides scientific background, while batch-specific documentation supports procurement review for laboratory research.

• Cardiogen is a short peptide sequence, and peptides are generally defined as short chains of amino acids joined by peptide bonds [2].
• PubChem lists H-Ala-Glu-Asp-Arg-OH with the one-letter sequence AEDR and computed molecular data relevant to compound identity review [1].
• Published Cardiogen research includes myocardial tissue culture work, fibroblast-related literature, and preclinical M-1 sarcoma model literature; these findings remain model-specific and should not become product claims [4] [6] [7].
• COA review should cover compound name, lot number, batch-specific testing, purity method, identity method, and label consistency.
• HPLC, LC-MS, and mass spectrometry can support peptide purity and identity review when paired with appropriate method details and batch records [12].
• Catalog amounts such as 20mg should be treated as listing specifications, not as experimental guidance.

Fast Answer: What Should Researchers Check Before They Buy Cardiogen for Research?

To buy Cardiogen for research, review RUO labeling, batch-specific COA documentation, HPLC or LC-MS identity data, lot traceability, and storage records before procurement review. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Cardiogen maps to the AEDR tetrapeptide entry listed by PubChem [1].

Cardiogen laboratory procurement review

Before you buy Cardiogen for research, compare peptide identity, supplier documentation, analytical testing, lot traceability, and research-use-only labeling. Published studies and the analytical record for a supplied lot answer different questions.

FDA guidance for RUO-labeled IVDs is not a peptide product rule, but it provides a useful labeling principle: RUO statements should align with research-only intent and should not support diagnostic positioning [20].

What Documentation Should Come First?

The first documents to review are the batch-specific certificate of analysis, the product label, the lot identifier, and any analytical records used to support identity or purity. FDA analytical-method guidance describes identity, quality, purity, and related attributes as central documentation concerns for analytical procedure submissions in regulated quality contexts [17].

For a research peptide page, the practical question is whether the product listing, COA, and batch records tell the same story. If the compound name, sequence, catalog amount, or lot number differs across documents, procurement teams should pause the review.

Why Does RUO Labeling Matter Before Procurement?

RUO labeling identifies the material as intended for laboratory research, not diagnostic, therapeutic, veterinary, cosmetic, supplement, or household use.

For Cardiogen research, RUO labeling should appear alongside documentation that supports technical review. The label should not be asked to carry scientific credibility by itself; it should be paired with a COA, test method notes, and lot-level traceability.

What Is Cardiogen in Bioregulator Peptide Research?

Cardiogen is commonly described in research literature and compound databases through the sequence H-Ala-Glu-Asp-Arg-OH, also represented as AEDR [1] . It appears in short-peptide bioregulation research and is supplied here for laboratory research only.

The broader Khavinson-linked literature discusses short peptides as gene-expression and protein-synthesis research subjects, but that literature should be treated as academic context rather than product-use guidance [8].

Cardiogen Peptide Identity and Sequence Context

A Cardiogen peptide listing should identify the canonical sequence, naming format, and molecular data. PubChem lists H-Ala-Glu-Asp-Arg-OH as AEDR, with computed molecular formula C18H31N7O9 and molecular weight 489.5 g/mol [1].

Sequence clarity matters because peptide identity is sequence-dependent. NCBI Bookshelf notes that peptide chains are formed from amino acid residues joined by peptide bonds, while primary structure resources describe peptide and protein sequences as ordered amino acid chains [2] [3].

Why Does a Synthetic Tetrapeptide Need Clear Documentation?

Cardiogen is a synthetic tetrapeptide, which means the listing should show that the intended four-residue sequence is the one being documented. A short peptide can still require careful identity review because sequence order, molecular mass, and analytical method details all affect interpretation.

Mass spectrometry is widely used for synthetic peptide characterization, including identity and purity evaluation [12]. That makes LC-MS or related mass data especially useful when a lab team is reviewing a Cardiogen research material.

How Amino Acid Context Supports Compound Review

The Ala-Glu-Asp-Arg sequence identifies the expected residues and gives analytical teams a reference for identity and mass review. Sequence information alone does not establish product performance.

By convention, peptide sequences are represented from the N-terminus to the C-terminus [3]. For Cardiogen documentation, that supports consistent comparison across a product listing, COA, chromatogram notes, and mass data.

Where Does Cardiogen Fit in Cardiovascular Research Models?

Cardiogen appears in cardiovascular bioregulator research because older literature examined myocardial tissue cultures and cardiac tissue models [4] . Those findings do not establish cardiovascular effects of a catalog product.

Cardiac Tissue Research

Published myocardial tissue culture research evaluated Cardiogen alongside individual amino acids in explant culture conditions from 3- and 24-month rat sources [4]. The study reported changes in cell proliferation and p53 protein expression under those model-specific conditions [4].

Those findings apply to the experimental conditions studied, not automatically to other materials or non-laboratory settings.

What Should Myocardial Model Literature Clarify?

The 2009 myocardial tissue culture paper examined cell proliferation and apoptosis-related p53 expression in organotypic culture [4] . Interpretation depends on the model, endpoints, assay conditions, and study limitations.

Myocardial tissue-culture findings do not establish functional outcomes outside the experimental system.

How Should Published Cardiogen Research Be Interpreted?

Published Cardiogen research consists of model-specific observations. Researchers can evaluate each study’s materials, methods, endpoints, and limitations separately from supplier documentation.

An evidence landscape helps separate model type from RUO interpretation:

What Can Preclinical Literature Establish?

Preclinical literature can establish what researchers examined in a specific model, under defined study conditions. It cannot establish a research-material claim for Pure Lab Peptides Cardiogen.

Cardiogen literature includes a myocardial tissue culture paper, a preclinical M-1 sarcoma model paper by Levdik and Knyazkin, and fibroblast signaling work in prostate-related culture systems [4] [6] [7] . These models require separate interpretation.

How In Vitro and Tissue Culture Models Shape Interpretation

In vitro and tissue culture models can help isolate cell-level or tissue-level research questions. The myocardial tissue culture study is relevant because it compared amino acids and the Cardiogen peptide in a controlled culture setting [4].

The limitation is equally important. A tissue culture finding is not a procurement claim, not a quality claim, and not a substitute for batch-specific analytical documentation.

Mechanistic Context in Cardiogen Research

Short peptide literature has discussed DNA-peptide interactions, histone interactions, and gene-expression models [8]. Another review reports that short peptides may bind DNA sequences in computational models, while noting that the broader mechanism remains an area of investigation [9].

Peptide Regulation, Cell Signaling, and Pathway Models

The 2021 systematic review describes short peptides in relation to gene expression, protein synthesis, histones, and DNA-peptide interactions [8].

Fibroblast and Cellular Findings

A PubMed-indexed gerontology paper examined short peptides including Cardiogen in relation to signaling factors of fibroblast differentiation in aging prostate-related cultures [7].

Those culture findings do not establish stromal, glandular, or tissue effects in other systems or of a supplier’s product.

How Do Study Conditions Affect Apoptosis and Cytostasis Findings?

Apoptosis and cytostasis findings depend on the study model and experimental conditions. p53 is a transcription factor involved in cell-cycle arrest and apoptosis decisions, and its functions are highly context-dependent [11] .

The Cardiogen myocardial tissue culture paper reported decreased p53 protein expression in that specific culture model [4] . This observation does not establish the behavior of a catalog product in other settings.

How Khavinson-Linked Bioregulator Literature Fits Cardiogen Research

Khavinson-linked literature is part of the Cardiogen research trail, but it should be treated as a literature cluster rather than as proof of product performance. Reviews by Khavinson and collaborators discuss short peptides, gene-expression regulation, and peptide bioregulation concepts [8] [9] [10].

This literature provides scientific background, but does not replace analytical testing, COA review, lot traceability, or supplier documentation.

What Do Historical Short Peptide Studies Add?

Historical short peptide studies add context around why AEDR appears in bioregulator peptide literature. Anisimov and Khavinson reviewed peptide bioregulation concepts and described synthesized di-, tri-, and tetrapeptide analogues in the broader research program [10].

For Cardiogen, these historical studies provide research background; they do not change the supplied material’s research-use-only status.

Using Author Names to Find Research Sources

Author names such as Khavinson, Levdik, and Knyazkin can help researchers locate relevant publications [6] [8] [10] . Authorship does not establish the performance or suitability of a supplier’s product.

How Research Literature Stays Separate From Product Claims

Why Study Findings Should Not Become Product Claims

Study findings depend on model design, assay conditions, endpoints, and source quality. The myocardial tissue culture paper and M-1 sarcoma model paper describe specific experimental settings, not product-page outcomes [4] [6].

Why Does COA Documentation Matter for Cardiogen?

COA documentation matters because it connects a specific lot to test data. For Cardiogen, a useful COA should help confirm that the batch under review matches the peptide identity described on the product page.

A COA does not answer every quality question. It should be read with method details, chromatogram or mass data where available, label consistency, and supplier documentation.

What COA Details Matter Before Labs Buy Cardiogen for Research?

Before labs buy Cardiogen for research, procurement teams should compare the compound name, sequence, molecular weight, lot number, testing date, method notes, and identity data. Analytical validation guidance from FDA and ICH Q2(R2) describes validation as a framework for evaluating analytical procedure performance characteristics [16].

Method-aware review examines the analytical procedures and records provided. It does not establish regulatory equivalence for a research peptide.

How Batch-Specific Records Support Research Procurement

Batch-specific records support procurement because they reduce ambiguity. A lot-level COA is more useful than a generic purity statement because it can be compared against the label and product listing.

WHO quality-control laboratory guidance also highlights documentation, laboratory records, and quality-management principles as part of reliable testing operations [18]. That makes batch documentation a practical research procurement issue.

Why Do COA Dates and Lot Numbers Matter?

COA dates and lot numbers help connect test records to the material being reviewed. Without that connection, a purity value or identity statement may not clearly apply to the specific listing.

Lot traceability is also important when a laboratory needs to compare records across procurement, receipt, storage, and internal inventory. The stronger the traceability chain, the easier it is to audit the research material record.

How Does Analytical Testing Support Cardiogen Peptide Identity?

Analytical testing supports Cardiogen peptide identity by comparing expected molecular and chromatographic information with measured data. Mass spectrometry is widely described as suitable for synthetic peptide identity and purity characterization [12].

For Cardiogen, testing can support the expected AEDR peptide identity, but does not guarantee biological activity.

How Does HPLC Support Peptide Purity Review?

HPLC can support peptide purity review by separating sample components under defined chromatographic conditions. For synthetic peptides, purity and identity review often requires method context, not only a single headline number [12] [14].

A Cardiogen COA should make clear whether the purity value comes from HPLC or another method.

How Does LC-MS Support Sequence and Mass Review?

LC-MS supports identity review by combining liquid chromatographic separation with mass spectrometric detection. Synthetic peptide literature describes LC-MS and MALDI-TOF-MS as common tools for confirming known peptide identity and purity [12].

For Cardiogen, LC-MS can help compare observed mass-related data against the expected AEDR peptide. Mass spectrometry data are typically represented by mass-to-charge ratio, or m/z, which links measured ions to mass-related interpretation [21].

What Can Chromatogram and Mass Data Confirm?

Chromatogram and mass data can confirm whether the observed signal is consistent with the expected peptide under the stated method. LC-ESI-MS literature has been used to identify known and unknown synthetic peptides based on molecular mass and sequence-related data [15].

These records are strongest when the COA, chromatogram, mass data, and lot number match. They are weaker when a product page gives only a generic purity statement.

What Should Researchers Compare Before They Buy Cardiogen for Research?

Researchers should compare the product listing, COA, label, lot record, test method, and storage documentation before they buy Cardiogen for research. This is a documentation review, not a product ranking exercise.

The most useful comparison is internal consistency. A clean documentation trail should make it easy to identify the compound, match the batch, and understand which analytical methods were used.

Product Listing Consistency Across Name, Sequence, and Amount

A Cardiogen product listing should keep name, sequence, and amount consistent across the page and COA. PubChem’s AEDR record gives a useful reference point for sequence and molecular data [1].

Where Catalog Amounts Fit Into Listing Review

Catalog amounts belong in product identification and inventory review. They help procurement teams confirm which listing is being evaluated, but they do not define research design.

Why Should Supplier Documentation Match the COA?

Supplier documentation should match the COA because the COA is only useful when it clearly maps to the material being reviewed. The product name, lot identifier, and method notes should align.

If the label, COA, and product page diverge, the uncertainty belongs in the procurement record. Research buyers should prioritize documentation clarity over marketing language.

What Storage and Handling Documentation Should Labs Review?

Storage and handling documentation should describe how the material should be logged, stored, and tracked in a laboratory inventory system. WHO storage and distribution guidance emphasizes storage conditions, documentation, stock control, equipment, and distribution risk management for medical products [19].

Labeling, Temperature, and Stability Notes

The label should identify the material and give storage information in a way that matches the supplier record. Storage notes should be recorded as documentation, not converted into performance claims.

Temperature and stability notes matter because research materials can be sensitive to storage conditions.

How Chain-of-Custody Records Support Laboratory Control

Chain-of-custody records help connect receipt, storage, access, and inventory review. This is useful when multiple research materials are stored in the same facility.

For Cardiogen, chain-of-custody documentation can include supplier record, purchase record, label image, COA, lot identifier, receipt date, and storage location. This helps laboratory teams maintain a clear audit trail.

How Research Teams Evaluate Cardiogen Before Procurement

Research teams evaluate Cardiogen by reviewing identity, documentation, analytical support, and RUO boundaries. The decision should be driven by records, not by unsupported claims.

A practical checklist can keep procurement review consistent:

• Verify that the compound is labeled for research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are paired with an analytical method.
• Check that the lot number on the COA matches the product documentation.
• Compare compound name, sequence, molecular weight, and catalog amount across records.
• Distinguish published study findings from evidence about the supplied lot.
• Document storage and handling conditions in a laboratory record.

What Should Procurement Teams Confirm First?

Procurement teams should confirm identity first: name, sequence, molecular data, and lot match. PubChem’s H-Ala-Glu-Asp-Arg-OH entry provides the AEDR reference point for sequence and computed mass [1].

Next, teams should review COA detail, test method, date, and laboratory source. A well-organized record helps the lab understand what was tested and which batch the record covers.

Why Third-Party Testing Adds Documentation Value

Third-party testing can add value when the report is batch-specific and method-aware. The value comes from independent analytical documentation, not from a promotional badge.

For synthetic peptides, mass spectrometry and LC-MS have been described as useful for identity and purity characterization [12] [13]. Research teams should still verify whether the report maps to the exact lot under review.

Common Misunderstandings in Cardiogen Research Procurement

Literature context, supplier statements, and lot-specific analytical evidence answer different questions.

Common misunderstandings include:

• Published literature does not equal product guidance.
• Preclinical findings should not be converted into non-laboratory claims.
• A purity percentage does not prove complete compound identity.
• A COA should be batch-specific.
• Pathway relevance does not equal product performance.
• Catalog amounts are listing specifications.

What Does Product Documentation Establish?

Product documentation helps research buyers assess identity, analytical support, lot traceability, and RUO status.

How Research Findings Differ From Commercial Claims

Research findings describe what investigators observed in a defined model. Commercial claims position a product as producing an outcome.

This distinction matters for Cardiogen because published studies examine apoptosis, cytostasis, fibroblast signaling, and M-1 sarcoma models under specific conditions [4] [6] [7] .

Documentation Review Before Labs Buy Cardiogen for Research

Documentation review before labs buy Cardiogen for research should be structured and repeatable. The goal is to confirm that the product listing, COA, analytical records, label, and supplier documentation align.

A laboratory documentation verification workflow can support that review:

1. Verify the compound name, AEDR sequence, lot number, and label match across documents.
2. Review the batch-specific COA.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS, mass spectrometry, or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date and laboratory source.
7. Record storage and handling requirements in the laboratory inventory file.

Final COA, Labeling, and Lot Traceability Checks

The final check should ask whether the Cardiogen listing, COA, label, and lot record all point to the same material. If they do, the documentation package is easier to review, archive, and audit.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

Where Should Cardiogen Research Questions Go Next?

Cardiogen research questions should go next to source review, COA review, analytical data review, and institutional procurement records. Research teams comparing peptide suppliers should prioritize COA availability, transparent labeling, and lot-level documentation.

Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.

FAQs

What does research use only mean for Cardiogen?

Research use only means Cardiogen is intended solely for qualified laboratory research. Review compound characterization, RUO labeling, batch documentation, COA data, and supplier records. Published findings do not establish suitability for personal or clinical use.

What should researchers consider before they buy Cardiogen for research?

Researchers should consider documentation first before they buy Cardiogen for research. A safe review should compare the product listing, COA, lot information, peptide identity, analytical testing records, and storage notes. Catalog details may help identify the listing, but the stronger procurement signal is whether the documentation package is batch-specific and internally consistent.

Why does a COA matter for Cardiogen research materials?

A COA matters for Cardiogen research materials because it connects a specific batch to documented analytical review. Researchers should check whether the COA includes identity, purity method, lot number, testing date, and supplier documentation. A peptide COA is most useful when it matches the product label and supports traceable research documentation.

How should published literature about Cardiogen be interpreted?

Published Cardiogen literature describes model-specific observations. Interpret in vitro studies, pathway research, and myocardial tissue-culture findings in light of their models, endpoints, methods, and limitations. These findings do not replace lot-specific analytical documentation.

What role does Cardiogen play in cardiovascular system research context?

Cardiovascular terms in the Cardiogen literature describe specific experimental models and observations. Findings involving vascular networks or signaling-factor expression do not establish effects or suitability of a catalog product.

What documentation should researchers review for Cardiogen handling records?

Cardiogen handling records support laboratory documentation control. Relevant records include label information, storage notes, lot traceability, batch documentation, supplier records, chromatograms, and analytical verification details.

---

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Vladimir Khatskelevich Khavinson

Author profile: RUDN Journal Profile

Vladimir Khatskelevich Khavinson authored and co-authored work on short peptides, gene expression, and peptide bioregulation. His publications provide background on short-peptide mechanisms and model-specific experimental findings.

Selected publications:

• Peptide Regulation of Gene Expression: A Systematic Review — Molecules, 2021. PMID: [34834147]
• A publication examining H-Ala-Glu-Asp-Arg-OH in cytoskeletal and nuclear matrix protein expression — Bulletin of Experimental Biology and Medicine, 2012. DOI: 10.1007/s10517-012-1766-9

Natalia Iosifovna Chalisova

Author profile: Molecular Medicine Author Details

Natalia Iosifovna Chalisova authored and co-authored publications on Cardiogen, organotypic tissue-culture models, and peptide bioregulators. Her work contributes to the myocardial model literature and provides context for interpreting findings under controlled experimental conditions.

Selected publications:

• A myocardial tissue-culture publication involving Cardiogen research models — Advances in Gerontology, 2009. PMID: [20210190]
• A publication on tissue-specific synthetic peptide-biologic regulators in organotypic tissue culture — Advances in Gerontology, 2006. PMID: [17152728]

REFERENCES

1. National Center for Biotechnology Information. PubChem Compound Summary for H-Ala-Glu-Asp-Arg-OH, CID 11583989. PubChem. Current database record.
2. Forbes Kaprive J, Krishnamurthy K. Biochemistry, Peptide. StatPearls, NCBI Bookshelf. Updated 2023.
3. Sanvictores T, Farci F. Biochemistry, Primary Protein Structure. StatPearls, NCBI Bookshelf. Updated 2025.
4. Chalisova NI, Lesniak VV, Balykina NA, et al. Myocardial tissue culture study involving amino acids and Cardiogen. Advances in Gerontology. 2009. PMID: 20210190.
5. Khavinson VKh, Lin’kova NS, Polyakova VO, Kvetnoy IM, Benberin VV, D’yakonov MM, Titkov YuS. Tetrapeptide H-Ala-Glu-Asp-Arg-OH and cytoskeletal/nuclear matrix protein expression. Bulletin of Experimental Biology and Medicine. 2012. DOI: 10.1007/s10517-012-1766-9.
6. Levdik NV, Knyazkin IV. M-1 sarcoma model study involving Cardiogen peptide. Bulletin of Experimental Biology and Medicine. 2009. PMID: 20396706. DOI: 10.1007/s10517-010-0730-9.
7. Kheĭfets OV, Poliakova VO, Kvetnoĭ IM. Fibroblast signaling-factor expression study involving short peptides and Cardiogen. Advances in Gerontology. 2010. PMID: 20586252.
8. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021. PMID: 34834147. PMCID: PMC8619776. DOI: 10.3390/molecules26227053.
9. Khavinson VKh, Lin’kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bulletin of Experimental Biology and Medicine. 2016. PMID: 27909961. DOI: 10.1007/s10517-016-3596-7.
10. Anisimov VN, Khavinson VKh. Peptide Bioregulation of Aging: Results and Prospects. Biogerontology. 2010. PMID: 19830585. DOI: 10.1007/s10522-009-9249-8.
11. Chen J. The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. Cold Spring Harbor Perspectives in Medicine. 2016. PMID: 26931810. PMCID: PMC4772082. DOI: 10.1101/cshperspect.a026104.
12. Prabhala BK, Mirza O, Højrup P, Hansen PR. Characterization of Synthetic Peptides by Mass Spectrometry. Methods in Molecular Biology. 2015. PMID: 26424265. DOI: 10.1007/978-1-4939-2999-3_9.
13. Smart SS, Mason TJ, Bennell PS, Maeji NJ, Geysen HM. High-throughput purity estimation and characterization of synthetic peptides by electrospray mass spectrometry. International Journal of Peptide and Protein Research. 1996. PMID: 8907499. DOI: 10.1111/j.1399-3011.1996.tb00809.x.
14. Li M, Josephs RD, Daireaux A, et al. Identification and quantification of structurally related peptide impurities by liquid chromatography-high resolution mass spectrometry. Analytical and Bioanalytical Chemistry. 2018. PMID: 29862433. DOI: 10.1007/s00216-018-1155-y.
15. D'Agostino PA, et al. LC/ESI-MS identification of synthetic peptides using electrospray ionization. Journal of Chromatography A. 1998. PMID: 9561756. DOI: 10.1016/S0021-9673(97)01104-7.
16. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA Guidance Document. 2024.
17. U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics. FDA Guidance Document. 2015.
18. World Health Organization. WHO Good Practices for Pharmaceutical Quality Control Laboratories. WHO Technical Report Series 1052, Annex 4. 2024.
19. World Health Organization. Good Storage and Distribution Practices for Medical Products. WHO Technical Report Series 1025, Annex 7. 2020.
20. U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance Document. 2013.
21. Garg E, Zubair M. Mass Spectrometer. StatPearls, NCBI Bookshelf. Updated 2024.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.